CSCO 2021 Live well to live long!

*It is only for medical professionals to read for reference.
Eribulin's efficacy and quality of life are both excellent, a new choice for advanced breast cancer chemotherapy drugs! The advent of the era of precision treatment has continuously improved the survival benefits of patients with advanced breast cancer
.

However, chemotherapeutics, as the most classic treatment, still have an important position in the rescue and treatment of advanced breast cancer
.

With the approval of eribulin at home and abroad, it has brought about a double-benefit improvement in the efficacy and quality of life for patients with advanced breast cancer, and has brought new changes to the chemotherapy pattern
.

On September 25, during the 2021 Chinese Society of Clinical Oncology (CSCO) held online, the Eisai Breast Tumor Satellite Symposium also met online as scheduled
.

This conference specially invited Professor Xu Binghe from the Cancer Hospital of the Chinese Academy of Medical Sciences and Professor Hu Xichun from the Cancer Hospital of Fudan University to co-chair, focusing on real-world research in the field of cancer and the impact of drug selection on the quality of life of advanced breast cancer for further analysis and Explore
.

The "medical community" hereby reports as a guest speaker! Conference Chair: Professor Xu Binghe from Cancer Hospital of Chinese Academy of Medical Sciences Conference Chair: Professor Hu Xichun, Fudan University Cancer Hospital It has been prolonged, but the psychological and physical pressure brought about by this has brought great troubles to patients, especially patients with advanced breast cancer
.

Professor Xu Binghe said in his speech that the "Healthy China 2030" Planning Outline and the National Comprehensive Cancer Network (NCCN) both take the quality of life of patients with advanced breast cancer into the category of concern
.

The quality of life of patients with advanced breast cancer is affected by many factors.
Among them, the perceivable adverse reactions caused by chemotherapy drugs affect the quality of life, treatment compliance and survival outcomes of patients.
This conference will further discuss these influencing factors
.

Peak Alignment-Multidisciplinary diagnosis and treatment opens a new era in the management of advanced breast cancer patients [Focus front] China's first advanced breast cancer quality of life concept survey and interpretation As the first speaker, Professor Ma Fei from the Cancer Hospital of the Chinese Academy of Medical Sciences shared China's advanced breast Investigation report on the survival status and quality of life of cancer patients
.

Professor Ma Fei pointed out that at present, the quality of life (QoL) of patients with advanced breast cancer in China is generally poor, and the 5-year overall survival rate is lower than that of European and American populations
.

Therefore, the quality of life of patients with advanced breast cancer in China deserves special attention
.

In view of the results of the "Survey on the Quality of Life of Patients with Advanced Breast Cancer in China", the problem of side-effect intolerance has gradually become prominent with the increase in the number of treatment lines, and the quality of life of patients with advanced breast cancer will be reduced
.

The decline in the quality of life will affect the patient's medication compliance, and ultimately affect the treatment outcome
.

The Chinese guidelines believe that the treatment of advanced breast cancer should be based on ensuring the quality of life of patients, controlling tumors, reducing symptoms, and prolonging survival
.

In the future, a patient-centered all-round interdisciplinary management model and a disease-centered multidisciplinary comprehensive diagnosis and treatment model should be formed, so as to improve the efficacy and quality of life of patients in an all-round way
.

Professor Ma Fei, Cancer Hospital of the Chinese Academy of Medical Sciences [Stones of Other Mountains] From the perspective of tumor neurology, the scientific prevention and control strategies of peripheral neuropathy caused by chemotherapy drugs are viewed from Professor Liu Mingsheng, Department of Neurology, Peking Union Medical College Hospital, from the early stage of chemotherapy-related peripheral neuropathy (CIPN) The four aspects of identification, early diagnosis, prevention and treatment explained that chemotherapeutics can cause related nervous system toxicity through various channels, thereby affecting the patient's quality of life and treatment compliance
.

Therefore, the occurrence of CINP needs to be identified, diagnosed and treated early, and appropriate management strategies should be adopted
.

Among these chemotherapeutics that cause peripheral neuropathy, eribulin can not only bring long-term benefits due to its unique mechanism of action, but also take into account a lower rate of perceivable adverse events, which makes the patient's quality of life and compliance Better
.

At present, it has been unanimously recommended as the preferred chemotherapy drug for metastatic breast cancer (MBC) by authoritative guidelines at home and abroad
.

Professor Liu Mingsheng from Peking Union Medical College Hospital of the Chinese Academy of Medical Sciences enjoys vitality-eribulin curative effect and quality of life provide a new choice of chemotherapy drugs for advanced breast cancer [vomiting old and new] From the quality of life of patients, the choice of chemotherapy drugs for advanced breast cancer is Fudan University Affiliated Tumor Professor Zhang Jian of the hospital said in this speech that the current domestic and foreign guidelines for the treatment of advanced breast cancer patients are to prolong overall survival (OS) and take QoL into account.
Among them, QoL is an important factor affecting the OS of advanced breast cancer patients.
The overall survival time of patients with good QoL is long
.

As the cornerstone of breast cancer treatment, chemotherapy is still the most important treatment for advanced breast cancer.
The perceptible adverse reactions caused by it are the direct cause of QoL in patients with advanced breast cancer.
Therefore, it is clinically important to find a chemotherapy regimen that takes both OS and QoL into consideration.
A goal that has been pursued
.

Eribulin can significantly prolong the OS of patients with advanced breast cancer, especially advanced triple-negative breast cancer (TNBC).
At the same time, patients can perceive the low incidence of adverse reactions, which can maximize the quality of life of patients.
Therefore, for MBC, especially TNBC and Eribulin are the preferred drugs for advanced chemotherapy in the post-yew era! Professor Zhang Jian from the Cancer Hospital of Fudan University [Integration of Knowledge and Action] Discussion on the Clinical Practice of Advanced Breast Cancer, Professor Wang Ying from Sun Yat-sen Memorial Hospital of Sun Yat-sen University, shared the "Eribulin Real World Research Data and Clinical Practice Exploration"
.

Professor Wang Ying said that from the real-world research progress of eribulin abroad, it can be seen that after the listing of eribulin, multiple real data in South Korea, the United States, Italy, and Japan have proved the efficacy and safety of eribulin for advanced breast cancer.
Compared with posterior-line treatment, the effect of front-line treatment is better; data from the real-world study of eribulin in China show that the first multi-center retrospective RWS study of eribulin in China proves that eribulin is independent Efficacy and safety can be balanced by drug or combination therapy; in terms of treatment mode, 48.
2% of Chinese patients choose eribulin combination therapy.
Multivariate analysis shows that the number of metastatic sites (1-2) and yew during MBC Treatment duration ≥ 6 months and combination therapy with bevacizumab were significantly associated with prolonged PFS; eribulin was generally safe, with only 6.
2% (17 cases) of patients discontinuing the drug due to AE, and only 7.
0% (19 cases) ) There is a dose reduction
.

In addition, Professor Wang Ying said that patients with different subtypes of advanced breast cancer receiving eribulin monotherapy or combined anti-HER2 targeted drugs/combined immunotherapy drugs can benefit patients, suggesting that eribulin can be used for Advanced breast cancer has broad treatment prospects, and eribulin is not only used in the posterior line, but also has a good effect in front-line applications
.

At the end of the meeting of Professor Wang Ying from Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Professor Hu Xichun concluded that chemotherapy is the cornerstone drug for advanced breast cancer.
After anthracycline and taxane chemotherapy drugs, eribulin is the first to conduct a head-to-head comparison.
And chemotherapeutics that can bring survival benefits to patients, so the application of chemotherapeutic drugs needs to be more standard, safer and more standardized
.

At present, in view of the national medical insurance policy, eribulin is often used in the third-line and above treatment of advanced breast cancer.
In fact, relevant evidence suggests that it can be used in clinical first-line treatment, especially for patients who are concerned about the quality of life
.

The patient report outcomes (PROs) also suggest that eribulin can improve the quality of life
.

Advanced breast cancer is an incurable disease.
In the post-yew era, the emergence of eribulin has made it possible for treatment to ensure curative effects and meet the requirements of quality of life, which will bring longer-term clinical benefits to Chinese patients
.

Eisai CSCO Enterprise Cloud Showroom